Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Altiratinib

    INTERMEDIATES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1345847-93-9, Dcc-2701, Dp-5164, Altiratinib [usan], Altiratinib (usan), 1,1-cyclopropanedicarboxamide, n-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-
    Molecular Formula
    C26H21F3N4O4
    Molecular Weight
    510.5  g/mol
    InChI Key
    GNNDEPIMDAZHRQ-UHFFFAOYSA-N
    FDA UNII
    T678746713
    Altiratinib is an orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities. Upon administration, altiratinib selectively binds to c-Met, VEGFR2, Tie2 and Trk tyrosine kinases, which may lead to the inhibition of endothelial cell migration, proliferation and survival. This also results in both an inhibition of tumor cell proliferation and increased tumor cell death in c-Met/VEGFR2/Tie2/Trk-expressing cells. These receptor tyrosine kinases (RTKs), frequently overexpressed or mutated by a variety of tumor cell types, play crucial roles in the regulation of angiogenesis, tumor cell growth and survival.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-N'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
    2.1.2 InChI
    InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)
    2.1.3 InChI Key
    GNNDEPIMDAZHRQ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F
    2.2 Other Identifiers
    2.2.1 UNII
    T678746713
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Dcc-2701

    2.3.2 Depositor-Supplied Synonyms

    1. 1345847-93-9

    2. Dcc-2701

    3. Dp-5164

    4. Altiratinib [usan]

    5. Altiratinib (usan)

    6. 1,1-cyclopropanedicarboxamide, N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-

    7. 1,1-cyclopropanedicarboxamide, N-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)-

    8. N-(4-((2-((cyclopropylcarbonyl)amino)pyridin-4-yl)oxy)-2,5-difluorophenyi)-n-(4- Fluorophenyl)cyclopropane-1,1-dicarboxamide

    9. T678746713

    10. 1-n'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

    11. N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.

    12. N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

    13. Unii-t678746713

    14. Altiratinib;dcc2701

    15. Altiratinib [inn]

    16. Altiratinib(dcc-2701)

    17. Altiratinib [who-dd]

    18. Schembl139906

    19. Gtpl9174

    20. Chembl3545365

    21. Dcc-270

    22. Dcc2701

    23. Ex-a902

    24. Bcp15682

    25. Hy-b0791

    26. Bdbm50193395

    27. Mfcd28900672

    28. Nsc784590

    29. S6412

    30. Akos026750329

    31. Zinc113198271

    32. Cs-3944

    33. Nsc-784590

    34. Sb18876

    35. Ncgc00480913-04

    36. Ac-35383

    37. N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

    38. Ft-0700171

    39. A14387

    40. D10862

    41. F11464

    42. A887875

    43. J-690136

    44. Q27074416

    45. 1,1-cyclopropanedicarboxamide, N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n-(4-fluorophenyl)-

    46. 4-{5-[(e)-2-{4-(2-chlorophenyl)-5-[5-(methylsulfonyl)-2-pyridinyl]-4h-1,2,4-triazol-3-yl}vinyl]-1,3,4-oxadiazol-2-yl}benzonitrile

    47. A9i

    48. N-1'-[4-[2-(cyclopropylcarbonylamino)pyridin-4-yl]oxy-2,5-bis(fluoranyl)phenyl]-n-1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; 1-n'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

    2.4 Create Date
    2011-12-05
    3 Chemical and Physical Properties
    Molecular Weight 510.5 g/mol
    Molecular Formula C26H21F3N4O4
    XLogP34.3
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count8
    Exact Mass510.15148965 g/mol
    Monoisotopic Mass510.15148965 g/mol
    Topological Polar Surface Area109 Ų
    Heavy Atom Count37
    Formal Charge0
    Complexity863
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1